Etikett: Nanexa

NANEXA: Clinical milestones align ahead of phase Ib/II and licensing push

Analys, Research

Nanexa continues to strengthen the foundation for the upcoming Phase Ib/II study in the NEX-22 project, with preliminary PK data from the...

Read More

NANEXA: Targeting treatment of first patient in phase Ib/II with NEX-22 before year-end

Analys, Research

Nanexa’s Q4 report did not reveal much new, although the conference call provided welcome clarity on the rationale behind the extension...

Read More

NANEXA: Financing secured into 2026 to drive NEX-22 development

Analys, Research

Johan Widmark | 2025-01-27 08:00  READ FULL REPORT HERE IN PDF With the directed issue of units amounting to SEK 35m, supplemented by SEK...

Read More

NANEXA: Progress for rival at Novo illustrates the significant value potential in Nanexa

Analys, Research

NEX-22 is progressing as expected, with the last patient in Phase I treated, results anticipated later in November, and Phase IIb scheduled...

Read More

NANEXA: NEX-22 Progress, Revaluation and Financing

Analys, Research

After initiating dosing of the first patient in June with Nanexa’s long-acting depot formulation of the GLP-1 analog liraglutide, NEX-22...

Read More

NANEXA: Insights from CMD underscore near- to mid-term opportunities with significant potential

Analys, Research

Apart from a slight further delay in the start of Phase I with NEX-22, the report for Q1’24 proved rather uneventful. The subsequent CMD...

Read More

NANEXA: Focus on dual GLP-1 opportunities and the partner projects

Analys, Research

Apart from a write down of capitalized development related to the suspended projects NEX-18 and NEX-20, there was not much new in...

Read More

NANEXA: Lining up to make Nanexa (close to) a pure GLP-1 play

Analys, Research

Following the focusing of the roadmap after the rights issue in October, Nanexa has now announced a further streamlining of its activities...

Read More

NANEXA: Raising our LOAs following a review of the projects

Analys, Research

With the dust settling after the recent rights issue, Nanexa now progresses with its more focused roadmap, concentrating on Phase I trials...

Read More

NANEXA: Outcome of rights issue forces an investor-friendly focus on core projects

Analys, Research

With a subscription rate of 34.7% of the rights issue, and a utilization of guarantee commitments corresponding to 27.1%, Nanexa is...

Read More

For new research on growth stocks, sign up to our newsletter